As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Scientific and medical experts are increasingly recognising obesity as a serious chronic disease.

10 hours ago · Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a www.clinicaltrials.gov entry.

2 days ago · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks. These topline results show early potential for …

As leaders in the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. We aim to be the leading force in the science behind obesity. Learn more about our ambitious R&D pipeline.

Jan 24, 2025 · The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

6 days ago · Novo Nordisk’s next-generation obesity treatment shows promise in early study. The study tested an injectable form of the drug, amycretin. Novo is also developing a pill form.

We are on a mission to increase awareness about obesity and its causes, destigmatise this chronic disease, and provide diverse treatment options. We are working towards a future where we can help prevent and treat obesity – and even ultimately cure it.

FORWARD was developed by Novo Nordisk Inc., in collaboration with a steering committee of obesity clinician experts, to address gaps in obesity education and support the preparation of future health care providers to diagnose, care for and treat people with obesity.

As leaders within the science of obesity, Novo Nordisk established the Transformational Prevention Unit (TPU) to tackle one of the world’s foremost health challenges and drive change within obesity prevention.

At Novo Nordisk, we are dedicated to making obesity a healthcare priority. We are committed to helping improve the lives of people with obesity by changing how the world sees, prevents and treats obesity.